$IMMU - On our trading list. had a great week, positive FDA drug application news and a Bull Flag chart pattern breakout.Immunomedics price target raised to $31 from $26 at H.C. WainwrightH.C. Wainwright analyst Raghuram Selvaraju raised his price target for Immunomedics to $31 from $26 after the FDA accepted the company's Biologics License Application for sacituzumab govitecan in third-line plus metastatic triplenegative breast cancer for review. While there is the possibility that the FDA could wait for the ASCENT trial data, which is expected in mid-2020, before making a final decision to approve the drug, sacituzumab should potentially reach the market in early Q3 of 2020, Selvaraju tells investors in a research note. The analyst points out that the FDA previously reviewed sacituzumab's efficacy and safety profile and that Immunomedics had a product label in hand, while the approval was solely subject to chemistry, manufacturing, and controls. Selvaraju reiterates a Buy rating on the shares. $IMMU, Immunomedics, Inc. / H1 Disclosure: I may trade in the ticker symbols mentioned, both long or short. My articles represent my personal opinion and analysis and should not be taken as investment advice. Readers should do their own research before making decisions to buy or sell securities. Trading and investing include risks, including loss of principal. If you liked this article, please click the LIKE (thumbs up) button. Feel free to leave any comments, question, or opinions. (Sign-up if you haven't already done so). Follow us/bookmark us and check back occasionally for additional articles or comments on our page... Wild Tiger Trading - start/main page